- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Granules India net profit rises 71 percent to Rs 164 crore in Q2
New Delhi: Drug firm Granules India on Tuesday reported a 70.82 per cent rise in its consolidated net profit to Rs 163.63 crore for the second quarter ended September 30, mainly on account of robust sales.
The company had posted a net profit of Rs 95.79 crore for the corresponding period previous fiscal, Granules India said in a BSE filing.
Consolidated revenue from operations stood at Rs 858.12 crore for the quarter under consideration. It was Rs 699.53 crore in the same period a year ago, it added.
"I am pleased to announce second consecutive robust performance by all our business segments, fuelled the 22.7 per cent growth in Q2FY21 revenues to Rs 858 crore," Granules India Chairman and MD Krishna Prasad Chigurupati said.
Read also: Granules India Dexmethylphenidate HCl ER capsules get USFDA approval to treat ADHD
The company''s Board has declared a second interim dividend of 25 paise per equity share of Re 1 each, the filing said.
Shares of Granules India Ltd were trading at Rs 393.55 per scrip on BSE, up 0.54 per cent from its previous close.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751